Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers Read More » June 26, 2025
RadioMedix Debuts Proprietary bench top 212Pb Generator to Support Targeted Alpha Therapy Development Read More » June 12, 2025
Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement for Next-Generation Radioligand Medicine Targeting Rare Cancers Read More » September 12, 2024
RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers Read More » May 16, 2024
RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors Read More » February 12, 2024
RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc. Read More » February 15, 2023
RadioMedix announces a $40 million Series A financing for the advancement of novel Targeted Alpha Therapy platform and diagnostic companion radiopharmaceuticals to address unmet needs in oncology. Michael Lee-Chin appointed to the board of the company. Read More » October 6, 2022
RadioMedix and Vect-Horus announce first dosing of Glioblastoma Multiforme and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH Read More » November 17, 2021
